Ken Griffin G1 Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.2 - $4.98 $499 - $1,130	227 Added 1891.67%	239 $0
Q1 2024 May 15, 2024	SELL	$2.1 - $4.83 $92,303 - $212,297	-43,954 Reduced 99.97%	12 $0
Q4 2023 Feb 14, 2024	SELL	$1.12 - $3.73 $108,474 - $361,257	-96,852 Reduced 68.78%	43,966 $134,000
Q3 2023 Nov 14, 2023	SELL	$1.22 - $2.67 $1,329 - $2,910	-1,090 Reduced 0.77%	140,818 $202,000
Q2 2023 Aug 14, 2023	BUY	$2.46 - $3.14 $98,756 - $126,055	40,145 Added 39.45%	141,908 $353,000
Q1 2023 May 15, 2023	SELL	$2.57 - $8.16 $496,421 - $1.58 Million	-193,160 Reduced 65.5%	101,763 $272,000
Q4 2022 Feb 14, 2023	BUY	$5.19 - $13.5 $1.01 Million - $2.62 Million	193,835 Added 191.75%	294,923 $1.6 Million
Q3 2022 Nov 14, 2022	SELL	$5.17 - $16.99 $1.19 Million - $3.92 Million	-230,806 Reduced 69.54%	101,088 $1.26 Million
Q2 2022 Aug 15, 2022	BUY	$4.04 - $8.51 $156,986 - $330,681	38,858 Added 13.26%	331,894 $1.64 Million
Q1 2022 May 16, 2022	BUY	$7.6 - $11.02 $194,795 - $282,453	25,631 Added 9.59%	293,036 $2.23 Million
Q4 2021 Feb 14, 2022	BUY	$10.16 - $16.17 $2.52 Million - $4.01 Million	247,871 Added 1268.92%	267,405 $2.73 Million
Q3 2021 Nov 15, 2021	SELL	$13.16 - $22.47 $297,258 - $507,552	-22,588 Reduced 53.63%	19,534 $262,000
Q2 2021 Aug 16, 2021	SELL	$19.57 - $26.32 $670,350 - $901,565	-34,254 Reduced 44.85%	42,122 $924,000
Q1 2021 May 17, 2021	SELL	$17.58 - $32.59 $1.79 Million - $3.32 Million	-102,004 Reduced 57.18%	76,376 $1.84 Million
Q4 2020 Feb 16, 2021	SELL	$10.99 - $20.4 $905,400 - $1.68 Million	-82,384 Reduced 31.59%	178,380 $3.21 Million
Q3 2020 Nov 16, 2020	BUY	$11.55 - $23.75 $2.09 Million - $4.29 Million	180,673 Added 225.58%	260,764 $3.01 Million
Q2 2020 Aug 14, 2020	SELL	$9.57 - $24.37 $432,353 - $1.1 Million	-45,178 Reduced 36.06%	80,091 $1.94 Million
Q1 2020 May 15, 2020	SELL	$9.07 - $26.32 $37,250 - $108,096	-4,107 Reduced 3.17%	125,269 $1.38 Million
Q4 2019 Feb 14, 2020	BUY	$20.54 - $31.0 $2.3 Million - $3.47 Million	111,852 Added 638.28%	129,376 $3.42 Million
Q3 2019 Nov 14, 2019	SELL	$22.78 - $40.58 $126,930 - $226,111	-5,572 Reduced 24.13%	17,524 $399,000
Q2 2019 Aug 14, 2019	SELL	$16.03 - $31.1 $4.09 Million - $7.94 Million	-255,412 Reduced 91.71%	23,096 $708,000
Q1 2019 May 15, 2019	BUY	$14.4 - $21.45 $1.54 Million - $2.29 Million	106,653 Added 62.06%	278,508 $0
Q4 2018 Feb 14, 2019	BUY	$16.51 - $51.33 $2.76 Million - $8.58 Million	167,210 Added 3599.78%	171,855 $3.29 Million
Q3 2018 Nov 13, 2018	SELL	$43.15 - $67.97 $158,748 - $250,061	-3,679 Reduced 44.2%	4,645 $0
Q1 2018 May 11, 2018	BUY	$19.05 - $41.76 $158,572 - $347,610	8,324 New	8,324 $308,000

Others Institutions Holding GTHX

# of Institutions

Shares Held

3.55M

Call Options Held

11.7K

Put Options Held

View Full List

About G1 Therapeutics, Inc.

Ticker GTHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,746,800
Market Cap $306M
Description
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...

More about GTHX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account